Sarepta therapeutics announces sale of priority review voucher for $102 million

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced it had completed the sale of its rare pediatric disease priority review voucher (prv). sarepta received a payment of $102 million upon completion of the sale. sarepta was awarded the prv following u.s. food and drug administration (fda) accelerated approval of elevidys (delandistrogene moxeparvovec-rokl) for the treatment of ambulatory pediatri.
SRPT Ratings Summary
SRPT Quant Ranking